Researchers uncover the source of cells that contribute to pulmonary fibrosis
Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.
pulmonologyadvisor22h
Guidance Developed for Diagnosis, Management of Eosinophilic Esophagitis
HealthDay News — In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are ...
Hosted on MSN1d
MAIA’s lung cancer therapy 99% more likely to improve OS over chemo alone
A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...
Science Daily1d
Molecular basis of food allergy
A multi-institutional study has identified one of the allergens responsible for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus. This is the first time one of the allergens ...
Air pollution drives lung cancer surge in non-smokers, study reveals
Air pollution is fueling a rise in the commonest form of lung cancer among non-smokers, hitting women and people in southeast ...
The Lancet2d
Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study
Estimated geographical and temporal distribution of lung-cancer incidence varied across the four main subtypes worldwide. Our ...
Novel study uncovers molecular basis of eosinophilic esophagitis food allergy
A multi-institutional study led by researchers at Children's Hospital of Philadelphia (CHOP) is the first to identify one of ...
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb.
The Lancet5d
Chronic obstructive pulmonary disease: new therapies and old needs
Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...